Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 May 3. doi: 10.1158/1078-0432.CCR-18-4142. [Epub ahead of print]

PMID:
31053602
2.

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E.

Br J Cancer. 2018 May;118(11):1425-1433. doi: 10.1038/s41416-018-0082-1. Epub 2018 May 16.

3.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MCU, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788b. No abstract available.

PMID:
28586336
4.

Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526c. No abstract available.

PMID:
28388604
5.

Large-scale implementation of the I-PASS handover system at an academic medical centre.

Shahian DM, McEachern K, Rossi L, Chisari RG, Mort E.

BMJ Qual Saf. 2017 Sep;26(9):760-770. doi: 10.1136/bmjqs-2016-006195. Epub 2017 Mar 9. Review.

PMID:
28280074
6.

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2016 Nov;22(11):1303-1313. doi: 10.1038/nm.4198. Epub 2016 Oct 24. Erratum in: Nat Med. 2017 Apr 7;23 (4):526. Nat Med. 2017 Jun 6;23 (6):788.

7.

Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow Left Ventricular Assist Devices.

Durand ML, Ennis SC, Baker JN, Camuso JM, McEachern KM, Kotton CN, Lewis GD, Garcia JP, MacGillivray TE.

Artif Organs. 2017 Feb;41(2):169-175. doi: 10.1111/aor.12726. Epub 2016 Apr 21.

PMID:
27098102
8.

The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS.

Mol Cell Biol. 2014 Jul;34(13):2517-32. doi: 10.1128/MCB.00147-14. Epub 2014 Apr 28.

9.

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D.

Blood. 2014 Feb 6;123(6):905-13. doi: 10.1182/blood-2013-04-495366. Epub 2013 Dec 20.

10.

Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.

Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V.

Mol Cancer Ther. 2014 Feb;13(2):386-98. doi: 10.1158/1535-7163.MCT-13-0420. Epub 2013 Dec 16.

11.

Ability of matrix models to explain the past and predict the future of plant populations.

Crone EE, Ellis MM, Morris WF, Stanley A, Bell T, Bierzychudek P, Ehrlén J, Kaye TN, Knight TM, Lesica P, Oostermeijer G, Quintana-Ascencio PF, Ticktin T, Valverde T, Williams JL, Doak DF, Ganesan R, McEachern K, Thorpe AS, Menges ES.

Conserv Biol. 2013 Oct;27(5):968-78. doi: 10.1111/cobi.12049. Epub 2013 Apr 8.

PMID:
23565966
12.

Iron-sulfide-bearing chimneys as potential catalytic energy traps at life's emergence.

Mielke RE, Robinson KJ, White LM, McGlynn SE, McEachern K, Bhartia R, Kanik I, Russell MJ.

Astrobiology. 2011 Dec;11(10):933-50. doi: 10.1089/ast.2011.0667. Epub 2011 Nov 23.

PMID:
22111762
13.

Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, Cheng SH.

PLoS One. 2010 Nov 24;5(11):e15033. doi: 10.1371/journal.pone.0015033.

14.

Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.

Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, Shayman JA, Grabowski GA, Scheule RK, Copeland DP, Cheng SH.

J Inherit Metab Dis. 2010 Jun;33(3):281-9. doi: 10.1007/s10545-010-9072-z. Epub 2010 Mar 25.

15.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M.

Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015.

16.

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.

McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J.

Mol Genet Metab. 2007 Jul;91(3):259-67. Epub 2007 May 16.

PMID:
17509920
17.

AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.

McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, Hutto E, Grabowski GA, Cheng SH, Marshall J.

J Gene Med. 2006 Jun;8(6):719-29.

PMID:
16528760
18.

BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities.

McEachern KA, Archey WB, Douville K, Arrick BA.

J Cell Biochem. 2003 May 1;89(1):120-32.

PMID:
12682913
19.

Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers.

Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, Borg A, Arrick BA.

Oncogene. 2002 Oct 10;21(46):7034-41.

20.

Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.

Marshall J, McEachern KA, Kyros JA, Nietupski JB, Budzinski T, Ziegler RJ, Yew NS, Sullivan J, Scaria A, van Rooijen N, Barranger JA, Cheng SH.

Mol Ther. 2002 Aug;6(2):179-89.

21.

The epidemiology of notified genital Chlamydia trachomatis infection in Victoria, Australia: a survey of diagnosing providers.

Thompson SC, McEachern KA, Stevenson EM, Forsyth JR.

Int J STD AIDS. 1997 Jun;8(6):382-7.

PMID:
9179649
22.

Politics in the journal?

McEachern KD.

Can Med Assoc J. 1980 May 10;122(9):996. No abstract available.

Supplemental Content

Loading ...
Support Center